Literature DB >> 23321329

Analysis of chemotactic molecules in bone marrow-derived mesenchymal stem cells and the skin: Ccl27-Ccr10 axis as a basis for targeting to cutaneous tissues.

Vitali Alexeev1, Adele Donahue, Jouni Uitto, Olga Igoucheva.   

Abstract

BACKGROUND AIMS: Adult stem cells produce a plethora of extracellular matrix molecules and have a high potential as cell-based therapeutics for connective tissue disorders of the skin. However, the primary challenge of the stem cell-based approach is associated with the inefficient homing of systemically infused stem cells to the skin.
METHODS: We examined chemotactic mechanisms that govern directional migration of mesenchymal stem cells (MSCs) into the skin by conducting a comprehensive expression analysis of chemotactic molecules in MSCs and defined cutaneous tissues from normal and hereditary epidermolysis bullosa (EB)-affected skin.
RESULTS: Analysis of chemokine receptors in short-term and long-term MSC cultures showed tissue culture-dependent expression of several receptors. Assessment of epidermis-derived and dermis-derived chemokines showed that most chemotactic signals that originate from the skin preferentially recruit different sets of leukocytes rather than MSCs. Analysis of the chemotactic molecules derived from EB-affected non-blistered skin showed only minor changes in expression of selected chemokines and receptors. Nevertheless, the data allowed us to define the Ccl27-Ccr10 chemotactic axis as the most potent for the recruitment of MSCs to the skin. Our in vivo analysis demonstrated that uniform expression of Ccr10 on MSCs and alteration of Ccl27 level in the skin enhance extravasation of stem cells from circulation and facilitate their migration within cutaneous tissue.
CONCLUSIONS: Collectively, our study provides a comprehensive analysis of chemotactic signals in normal and EB-affected skin and proof-of-concept data demonstrating that alteration of the chemotactic pathways can enhance skin homing of the therapeutic stem cells.
Copyright © 2013 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23321329      PMCID: PMC3551218          DOI: 10.1016/j.jcyt.2012.11.006

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  40 in total

1.  Targeted overexpression of IL-18 binding protein at the central nervous system overrides flexibility in functional polarization of antigen-specific Th2 cells.

Authors:  Sagie Schif-Zuck; Juergen Westermann; Nir Netzer; Yaniv Zohar; Moran Meiron; Gizi Wildbaum; Nathan Karin
Journal:  J Immunol       Date:  2005-04-01       Impact factor: 5.422

2.  The chemokine receptor CCX-CKR mediates effective scavenging of CCL19 in vitro.

Authors:  Iain Comerford; Sandra Milasta; Valerie Morrow; Graeme Milligan; Robert Nibbs
Journal:  Eur J Immunol       Date:  2006-07       Impact factor: 5.532

3.  Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis.

Authors:  Yaojiong Wu; Liwen Chen; Paul G Scott; Edward E Tredget
Journal:  Stem Cells       Date:  2007-07-05       Impact factor: 6.277

4.  CTACK/CCL27 accelerates skin regeneration via accumulation of bone marrow-derived keratinocytes.

Authors:  Daisuke Inokuma; Riichiro Abe; Yasuyuki Fujita; Mikako Sasaki; Akihiko Shibaki; Hideki Nakamura; James R McMillan; Tadamichi Shimizu; Hiroshi Shimizu
Journal:  Stem Cells       Date:  2006-08-24       Impact factor: 6.277

5.  Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors.

Authors:  Marek Honczarenko; Yi Le; Marcin Swierkowski; Ionita Ghiran; Aleksandra M Glodek; Leslie E Silberstein
Journal:  Stem Cells       Date:  2005-10-27       Impact factor: 6.277

6.  Towards in situ tissue repair: human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2.

Authors:  Jochen Ringe; Sandra Strassburg; Katja Neumann; Michaela Endres; Michael Notter; Gerd-Rüdiger Burmester; Christian Kaps; Michael Sittinger
Journal:  J Cell Biochem       Date:  2007-05-01       Impact factor: 4.429

7.  Innate immune activation of CD4 T cells in salmonella-infected mice is dependent on IL-18.

Authors:  Aparna Srinivasan; Rosa-Maria Salazar-Gonzalez; Michael Jarcho; Michelle M Sandau; Leo Lefrancois; Stephen J McSorley
Journal:  J Immunol       Date:  2007-05-15       Impact factor: 5.422

8.  The surface adhesion molecule CXCR4 stimulates mesenchymal stem cell migration to stromal cell-derived factor-1 in vitro but does not decrease apoptosis under serum deprivation.

Authors:  Shyam Bhakta; Ping Hong; Omer Koc
Journal:  Cardiovasc Revasc Med       Date:  2006 Jan-Mar

9.  Autologous bone marrow-derived cultured mesenchymal stem cells delivered in a fibrin spray accelerate healing in murine and human cutaneous wounds.

Authors:  Vincent Falanga; Satori Iwamoto; Molly Chartier; Tatyana Yufit; Janet Butmarc; Nicholas Kouttab; David Shrayer; Polly Carson
Journal:  Tissue Eng       Date:  2007-06

10.  Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model.

Authors:  Keiji Hirota; Hiroyuki Yoshitomi; Motomu Hashimoto; Shinji Maeda; Shin Teradaira; Naoshi Sugimoto; Tomoyuki Yamaguchi; Takashi Nomura; Hiromu Ito; Takashi Nakamura; Noriko Sakaguchi; Shimon Sakaguchi
Journal:  J Exp Med       Date:  2007-11-19       Impact factor: 14.307

View more
  17 in total

Review 1.  The Role of Chemokines in Mesenchymal Stem Cell Homing to Wounds.

Authors:  Anne M Hocking
Journal:  Adv Wound Care (New Rochelle)       Date:  2015-11-01       Impact factor: 4.730

2.  Pro-Inflammatory Chemokines and Cytokines Dominate the Blister Fluid Molecular Signature in Patients with Epidermolysis Bullosa and Affect Leukocyte and Stem Cell Migration.

Authors:  Vitali Alexeev; Julio Cesar Salas-Alanis; Francis Palisson; Lila Mukhtarzada; Giulio Fortuna; Jouni Uitto; Andrew South; Olga Igoucheva
Journal:  J Invest Dermatol       Date:  2017-07-20       Impact factor: 8.551

Review 3.  Placenta-based therapies for the treatment of epidermolysis bullosa.

Authors:  Christopher Nevala-Plagemann; Catherine Lee; Jakub Tolar
Journal:  Cytotherapy       Date:  2015-03-18       Impact factor: 5.414

Review 4.  Mesenchymal stem cells: From regeneration to cancer.

Authors:  Peishan Li; Zheng Gong; Leonard D Shultz; Guangwen Ren
Journal:  Pharmacol Ther       Date:  2019-04-16       Impact factor: 12.310

5.  Cxcr6-Based Mesenchymal Stem Cell Gene Therapy Potentiates Skin Regeneration in Murine Diabetic Wounds.

Authors:  Neha R Dhoke; Komal Kaushik; Amitava Das
Journal:  Mol Ther       Date:  2020-02-14       Impact factor: 11.454

6.  The Chemokine Receptors Ccr5 and Cxcr6 Enhance Migration of Mesenchymal Stem Cells into the Degenerating Retina.

Authors:  Martina Pesaresi; Sergi A Bonilla-Pons; Ruben Sebastian-Perez; Umberto Di Vicino; Marc Alcoverro-Bertran; Ralph Michael; Maria Pia Cosma
Journal:  Mol Ther       Date:  2020-12-01       Impact factor: 11.454

7.  Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa.

Authors:  Christopher Perdoni; John A McGrath; Jakub Tolar
Journal:  Stem Cell Res Ther       Date:  2014-11-06       Impact factor: 6.832

Review 8.  Enhancing the migration ability of mesenchymal stromal cells by targeting the SDF-1/CXCR4 axis.

Authors:  Leah A Marquez-Curtis; Anna Janowska-Wieczorek
Journal:  Biomed Res Int       Date:  2013-12-05       Impact factor: 3.411

Review 9.  Advances in understanding and treating dystrophic epidermolysis bullosa.

Authors:  Michael J Vanden Oever; Jakub Tolar
Journal:  F1000Prime Rep       Date:  2014-05-06

10.  Chemotaxis-driven disease-site targeting of therapeutic adult stem cells in dystrophic epidermolysis bullosa.

Authors:  Vitali Alexeev; Adele Donahue; Jouni Uitto; Olga Igoucheva
Journal:  Stem Cell Res Ther       Date:  2016-08-27       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.